Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record.

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

Open access
Lin, Tse-I, Lenz, Oliver, Fanning, Gregory, Verbinnen, Thierry, Delouvroy, Frédéric, Scholliers, Annick, Vermeiren, Katrien, Rosenquist, Åsa, Edlund, Michael, Samuelsson, Bertil, Vrang, Lotta, de Kock, Herman, Wigerinck, Piet, Raboisson, Pierre, Simmen, Kenneth·2009·Antimicrobial Agents and Chemotherapy

Abstract

The hepatitis C virus (HCV) NS3/4A serine protease has been explored as a target for the inhibition of viral replication in preclinical models and in HCV-infected patients. TMC435350 is a highly specific and potent inhibitor of NS3/4A protease selected from a series of novel macrocyclic inhibitors. In biochemical assays using NS3/4A proteases of genotypes 1a and 1b, inhibition constants of 0.5 and 0.4 nM, respectively, were determined. TMC435350 inhibited HCV replication in a cellular assay (subgenomic 1b replicon) with a half-maximal effective concentration (EC 50) of 8 nM and a selectivity index of 5,875. The compound was synergistic with alpha interferon and an NS5B inhibitor in the replicon model and additive with ribavirin. In rats, TMC435350 was extensively distributed to the liver and intestinal tract (tissue/plasma area under the concentration-time curve ratios of >35), and the absolute bioavailability was 44% after a single oral administration. Compound concentrations detected in both plasma and liver at 8 h postdosing were above the EC 99 value measured in the replicon. In conclusion, given the selective and potent in vitro anti-HCV activity, the potential for combination with other anti-HCV agents, and the favorable pharmacokinetic profile, TMC435350 has been selected for clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.01058-08

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Lin, T.-I., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., Vrang, L., de Kock, H., Wigerinck, P., Raboisson, P., & Simmen, K.
Venue
Antimicrobial Agents and Chemotherapy
Published
2009-04
Volume
53
Issue
4
Pages
1377-1385
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2159414436
Cited by
188
References
0
FWCI
11.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. https://app.cochat.ai/papers/10.1128/aac.01058-08
The paper
Lin, T.-I., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., Vrang, L., de Kock, H., Wigerinck, P., Raboisson, P., & Simmen, K. (2009). In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01058-08

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.